| Old Articles: <Older 5201-5210 Newer> |
|---|
 |
Chemistry World
October 23, 2008
Matt Wilkinson |
Merck to slash more jobs Beleaguered US pharma giant, Merck & Co., has announced new restructuring plans that will see the company cut 7,200 jobs in an effort to save up to $4.2 billion   |
The Motley Fool
October 23, 2008
Brian Orelli |
Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it. |
The Motley Fool
October 23, 2008
Brian Orelli |
Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter. |
The Motley Fool
October 22, 2008
Jim Mueller |
Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated. |
The Motley Fool
October 22, 2008
Brian Orelli |
Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013. |
The Motley Fool
October 22, 2008
Brian Orelli |
Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent. |
The Motley Fool
October 22, 2008
Brian Orelli |
Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places. |
Fast Company
November 2008
Tim McKeough |
Intercell's Needle-Free Vaccines A needle-free vaccination method is being developed by Intercell USA with help from design giant Ideo. |
The Motley Fool
October 21, 2008
Brian Orelli |
Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter. |
The Motley Fool
October 21, 2008
Brian Orelli |
The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch. |
| <Older 5201-5210 Newer> Return to current articles. |
